Breast Cancer | Specialty

Dr. Mahtani on Side Effects of Ovarian Suppression in Breast Cancer

April 9th 2018

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses side effects of ovarian suppression in patients with breast cancer.

Treatments Emerging to Combat Endocrine Resistance in ER+ Breast Cancer

April 6th 2018

Heather Han, MD, discusses emerging approaches for combating endocrine resistance in patients with ER-positive breast cancer.

Distinctive Features of Male Breast Cancer Identified

April 5th 2018

An analysis of clinical characteristics, gene expression, and 21-gene Breast Recurrence Score results identified distinctive biologic features of breast cancer in men.

Dr. Domchek Discusses Areas of Investigation in Breast Cancer

April 4th 2018

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses areas of investigation in breast cancer.

Excitement Grows About PARP Inhibitors in BRCA-Mutated TNBC

April 4th 2018

A panel of experts discusses the role of BRCA1/2 mutation testing and how and when to incorporate PARP inhibitors into the care of patients with BRCA-positive TNBC.

EMA to Review Olaparib in BRCA-mutated, HER2-negative Breast Cancer

April 3rd 2018

The European Medicines Agency has accepted a marketing authorization application for olaparib to treat women with BRCA-mutated, HER2-negative metastatic breast cancer who previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.

Dr. Durand Discusses Treatment Options for Toxicities from Therapy in HER2+ Breast Cancer

April 2nd 2018

Jean-Bernard Durand, MD, professor in the Department of Cardiology at The University of Texas MD Anderson Cancer Center, discusses advice for community oncologists on managing patients that are experiencing symptoms from treatment for HER2-positive breast cancer.

AKT Inhibitor May Overcome Chemotherapy Resistance in 2 Breast Cancer Subtypes

April 2nd 2018

A novel inhibitor that targets the AKT node in the PI3K pathway may offer a treatment option in cases of resistance to chemotherapy in 2 patient populations: triple-negative breast cancer or ER-positive/HER2-negative breast cancer with certain molecular aberrations.

Dr. Pegram on Developing Agents for Patients With HER2+ Breast Cancer and Brain Metastases

April 2nd 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses developing agents for patients with HER2-positive breast cancer who have brain metastases.

Dr. Khong on the Benefit of Neoadjuvant Endocrine Therapy in ER+ Breast Cancers

March 30th 2018

Hung T. Khong, MD, medical oncologist, Moffitt Cancer Center, discusses the use of neoadjuvant endocrine therapy.

Dr. Han on the Differences Between CDK 4/6 Inhibitors in ER+ Breast Cancer

March 30th 2018

Heather S. Han, MD, research director, medical oncologist, Department of Breast Oncology, Moffitt Cancer Center, discusses the differences between CDK 4/6 inhibitors, and their efficacy as both single- and combination agents.

Final Insight: PARPs and gBRCA in Breast Cancer

March 30th 2018

Testing for Germline BRCA Mutations in the Future

March 30th 2018

PARP Inhibitors in Other Subtypes of Breast Cancer

March 30th 2018

Distinguishing Between PARP Inhibitors in Breast Cancer

March 30th 2018

PARP Inhibitors and Platinum Sensitivity or Resistance

March 30th 2018

Additional PARPs Under Investigation for Breast Cancer

March 30th 2018

Using Olaparib in gBRCA1/2+ Breast Cancer

March 30th 2018

Olaparib: Predicting Response in Breast Cancer

March 30th 2018

Takeaways From the OlympiAD Trial

March 30th 2018